<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We compared the outcomes of unrelated donor (URD, n = 358) with human leukocyte antigen (HLA)-matched sibling donor (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e>, n = 226) transplantations in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in first complete remission (CR1) having unfavorable cytogenetics at diagnosis </plain></SENT>
<SENT sid="1" pm="."><plain>Unfavorable cytogenetic abnormalities were: complex (â‰¥ 3 abnormalities), 32%; and noncomplex involving chromosome 7, 25%; chromosome 5, 9%; 11q or MLL rearrangements, 18%; t(6;9), 5%; and other noncomplex, 10% </plain></SENT>
<SENT sid="2" pm="."><plain>URDs were HLA-well-matched (n = 254; 71%) or partially-matched (n = 104; 29%) </plain></SENT>
<SENT sid="3" pm="."><plain>Three-year <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e>) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> was 42% (95% confidence interval [CI], 35%-48%) compared with 34% (95% CI, 28%-41%) for HLA-well-matched URD and 29% (95% CI, 20%-39%) for partially-matched URD (P = .08) </plain></SENT>
<SENT sid="4" pm="."><plain>In multivariate analysis, HLA-well-matched URD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> yielded similar <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> (relative risk [RR] = 1.1, 95% CI, 0.86-1.40, P = .44) and overall survival (OS; RR = 1.06, 95% CI, 0.83-1.37, P = .63) </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> and OS were significantly inferior for HLA-partially-matched URD recipients, those with prior <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, and those older than 50 years </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cytogenetic cohorts had similar outcomes </plain></SENT>
<SENT sid="7" pm="."><plain>Patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> had a significantly lower risk of relapse (RR = 0.68, 95% CI, 0.47-0.99, P = .05) </plain></SENT>
<SENT sid="8" pm="."><plain>Hematopoietic cell transplantation (HCT) using HLA-well-matched URD and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSD</z:e> resulted in similar <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LFS</z:e> and OS in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients in CR1 with unfavorable cytogenetics </plain></SENT>
<SENT sid="9" pm="."><plain>Outcomes of HCT from HLA-partially- matched URD were inferior </plain></SENT>
</text></document>